stockrow
Wednesday 4 November 2026
Export CAPR’s income statement to Excel — free account
Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023.
- Revenue
- −7.92%
- EPS
- −22.8%
- Free cash flow
- −72.9%
Quarter to June 2026, against a year earlier
8.89
0.65
+7.89%
Follow CAPR
Alert me
Capricor Therapeutics, Inc. (CAPR) P/E ratio
Capricor Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 69.7× (January 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 52.3× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 69.7×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ASMB Assembly Biosciences, Inc. compare | n/m |
| MNPR Monopar Therapeutics Inc. compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| CAPR Capricor Therapeutics, Inc. | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| CRMD CorMedix Inc compare | 2.3× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.6× |
| Market median | 18.3× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)